SEC Form 4 · accession 0001437749-17-010677
LIFECORE BIOMEDICAL, INC. \DE\ · LFCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James G Hall
Officer — Executive Vice President
Period of report
Jun 1, 2017
Accepted (ET)
Jun 5, 2017 · 7:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005286
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (Right to Buy)F2 | $14.00 | Jun 1, 2017 | M | 75,000 | A | Jul 1, 2017 | Jun 1, 2024 | Common Stock | 75,000 | 75,000 | D |
| Right to Buy Restricted Stock Unit (RSU)F1,F3 | — | Jun 1, 2017 | M | 25,000 | A | Jun 1, 2020 | — | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
- F21/36 of the grant becomes exercisable on each monthly anniversary of the grant date, June 1, 2017.
- F3Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit.